Sign In
Buy BCDA
$0.82
+0.0531 (+6.89%)
At Close: Jul 31, 2026
BioCardia, Inc. (BCDA) Q1 2024 Earnings Call Transcript
11:00pm, Tuesday, 14'th May 2024
BioCardia, Inc. (NASDAQ:BCDA ) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Miranda Peto - IR Peter Altman - President and CEO David McClung - CFO Conference Call Part
BioCardia Reports First Quarter 2024 Business Highlights and Financial Results
04:02pm, Tuesday, 14'th May 2024
SUNNYVALE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, t
BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024
07:00am, Thursday, 09'th May 2024
SUNNYVALE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, t
BioCardia's CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes
07:00am, Wednesday, 01'st May 2024
SUNNYVALE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, t
BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort
09:00am, Thursday, 25'th Apr 2024
Call Scheduled for Study Clinical Leadership to Discuss Results and Details on Pivotal Randomized Trial Call Scheduled for Study Clinical Leadership to Discuss Results and Details on Pivotal Randomize
BioCardia, Inc. (BCDA) Q4 2023 Earnings Call Transcript
08:00pm, Wednesday, 27'th Mar 2024
BioCardia, Inc. (BCDA) Q4 2023 Earnings Call Transcript
BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results
04:00pm, Wednesday, 27'th Mar 2024
SUNNYVALE, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease
BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024
07:00am, Wednesday, 20'th Mar 2024
SUNNYVALE, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,
BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership
07:00am, Wednesday, 13'th Mar 2024
BioCardia & StemCardia biotechnology company partnership targets heart failure, the leading cause of death and a condition with limited treatment options
BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study
07:00am, Tuesday, 12'th Mar 2024
Centers for Medicare & Medicaid Services (CMS) approves reimbursement coverage of the confirmatory Phase III clinical trial of CardiAMP heart failure study
SUNNYVALE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (Nasdaq: BCDA), a biotechnology company focused on advancing late-stage cell therapy interventions for cardiovascular disorders,
BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA
07:00am, Thursday, 08'th Feb 2024
SUNNYVALE, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (“BioCardia” or the “Company”) (Nasdaq: BCDA), a biotechnology company focused on advancing late-stage cell therapy interv
BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference
07:00am, Wednesday, 31'st Jan 2024
SUNNYVALE, Calif., Jan. 31, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (“BioCardia” or the “Company”) (Nasdaq: BCDA), a biotechnology company focused on advancing late-stage cell therapy interv
BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders
07:00am, Wednesday, 03'rd Jan 2024
SUNNYVALE, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. (Nasdaq: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,
SUNNYVALE, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease,
